CorMedix director granted 30,453 restricted stock units

CorMedix Inc. director Janet Dillione received an equity grant of 30,453 shares of common stock in the form of restricted stock units.

Rhea-AI Filing Summary

CorMedix Inc. director Janet Dillione received an equity grant of 30,453 shares of common stock in the form of restricted stock units. The units were issued on January 26, 2026 at a stated price of $0.00 per share and represent a right to receive an equal number of common shares.

The restricted stock units will vest in full on January 26, 2027, conditioned on continued service through that date. Following this grant, Dillione beneficially owns 68,926 shares of CorMedix common stock in direct ownership.

Insider Trade Summary

Grant/Award: 30,453 shares

Grant/Award 1 txn

Insider Dillione Janet

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	30,453	$0.00	$0.00

Holdings After Transaction: Common Stock — 68,926 shares (Direct)

Footnotes (1)

1. F1. These shares represent restricted stock units issued on January 26, 2026. Each restricted stock unit represents the right to receive one share of CorMedix Inc. common stock. These restricted stock units will vest in full on January 26, 2027, subject to continued service on the vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did CorMedix (CRMD) report for Janet Dillione?

CorMedix reported that director Janet Dillione received 30,453 restricted stock units of common stock. The award was granted on January 26, 2026 and increases her directly held beneficial ownership to 68,926 shares after the transaction.

What type of securities did Janet Dillione receive from CorMedix (CRMD)?

Janet Dillione received restricted stock units that each represent the right to receive one share of CorMedix common stock. These units function as equity-based compensation and convert into common shares upon vesting, assuming all vesting conditions are met.

When do Janet Dillione’s CorMedix (CRMD) restricted stock units vest?

The restricted stock units granted to Janet Dillione vest in full on January 26, 2027. Vesting is subject to her continued service through the vesting date, meaning she must remain in her role until that date to receive the underlying shares.

How many CorMedix (CRMD) shares does Janet Dillione own after this Form 4 transaction?

After the reported grant, Janet Dillione beneficially owns 68,926 shares of CorMedix common stock. This figure reflects her direct ownership following the award of 30,453 restricted stock units that were issued on January 26, 2026 at a stated price of $0.00.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/27/2026 - 09:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dillione Janet

(Last) (First) (Middle)

C/O CORMEDIX INC.

389 INTERPACE PKWY, SUITE 450

(Street)

PARSIPPANY NJ 07054

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CorMedix Inc. [ CRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/26/2026		A		30,453	A	$0.00(1)	68,926	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares represent restricted stock units issued on January 26, 2026. Each restricted stock unit represents the right to receive one share of CorMedix Inc. common stock. These restricted stock units will vest in full on January 26, 2027, subject to continued service on the vesting date.

	/s/ Beth Zelnick Kaufman, attorney-in-fact	01/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.